Subsequent cholangiocarcinoma after pancreaticoduodenectomy: a case study

Background

Metachronous cholangiocarcinoma following pancreaticoduodenectomy is a rare but significant complication that complicates patient management. The Whipple procedure is the standard treatment for periampullary neoplasms. Understanding these risks is crucial for ongoing patient surveillance and management strategies.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• A 62-year-old male developed hilar cholangiocarcinoma 9 years after a Whipple procedure.
• The patient had a history of a duodenal papillary villous tubular adenoma with moderate dysplasia.
• Imaging revealed a hepatic hilar mass and intrahepatic biliary dilation, leading to a diagnosis of poorly differentiated cholangiocarcinoma.
• Migrated internal pancreaticojejunostomy stent was identified during intraoperative exploration, potentially contributing to carcinogenesis.
• Immunohistochemical analysis indicated a sporadic origin of the cholangiocarcinoma.

Clinical Implications

Healthcare professionals should consider the possibility of second primary malignancies in patients with late-onset biliary obstruction after pancreaticoduodenectomy.

Conclusion

This case highlights potential complications associated with indwelling surgical stents in patients post-pancreaticoduodenectomy.

Related Resources & Content

1. Impact of Internal Pancreatic Duct Stenting on Long-Term Outcomes of Pancreaticojejunostomy Stenosis After Pancreaticoduodenectomy, 2025 -- Springer
2. Favorable long-term outcomes following concurrent resection of the esophagus, stomach, and pancreas, 2008 -- Springer
3. Evaluating the Efficacy of Pancreatico-Jejunostomy on an Isolated Loop Following Pancreatico-Duodenectomy, 2022 -- Springer
4. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma, 2024 -- EASL Campus
5. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1), 2024 -- ScienceDirect
6. Assessment of Functional, Biological, and Radiological Outcomes of Pancreaticojejunal Anastomosis One Year Post-Pancreatoduodenectomy: A Prospective Investigation
7. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma | EASL Campus
8. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study - ScienceDirect
9. Late Development of Bile Duct Cancer in Patients Who Had Biliary-Enteric Drainage for Benign Disease: A Follow-Up Study of More Than 1,000 Patients - PMC